Sartorius Stedim Biotech (FR:DIM)
:DIM
Top Page
Sartorius Stedim Biotech
(DIM)
Select Model
Select Model
Rating:52Neutral
Price Target:
€165.00
▼(-8.74% Downside)
Action:ReiteratedDate:02/22/26
The score is driven primarily by mixed financial performance: strong TTM revenue rebound and improved profitability/leverage are offset by weak cash conversion and declining free cash flow. Technical signals are also a headwind with price below key moving averages and negative MACD. Valuation further pressures the score due to a high P/E and minimal dividend yield.
Positive Factors
Recurring consumables & services
Sartorius Stedim Biotech’s business model relies on repeatable consumables and installed-base services, creating predictable, recurring revenue and higher customer retention. This aftermarket mix supports steady demand and revenue visibility across manufacturing cycles, strengthening durable cash flow potential.
Negative Factors
Weak free cash flow conversion
Significant FCF decline and low cash conversion versus net income weaken the company’s ability to self-fund capex, repay debt, or increase shareholder distributions. Persistent weak conversion pressures financial flexibility and makes the firm more reliant on external financing for growth or working capital needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables & services
Sartorius Stedim Biotech’s business model relies on repeatable consumables and installed-base services, creating predictable, recurring revenue and higher customer retention. This aftermarket mix supports steady demand and revenue visibility across manufacturing cycles, strengthening durable cash flow potential.
Read all positive factors
Sartorius Stedim Biotech (DIM) vs. iShares MSCI France ETF (EWQ)
Market Cap
€16.93B
Dividend Yield0.31%
Average Volume (3M)78.09K
Price to Earnings (P/E)76.9
Beta (1Y)1.26
Revenue Growth7.72%
EPS Growth53.84%
CountryFR
Employees9,961
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.12
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€233.00Price Target Upside28.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)5.15
Revenue Forecast (FY)€3.17B
Sartorius Stedim Biotech Business Overview & Revenue Model
Company Description
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separa...
How the Company Makes Money
The company makes money primarily by selling bioprocessing products and solutions to biopharmaceutical manufacturers and related life-science customers. A major component of its revenue comes from recurring sales of consumables used in ongoing pro...
Sartorius Stedim Biotech Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
63
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.97B | 2.78B | 2.78B | 3.49B | 2.89B |
| Gross Profit | 1.35B | 1.21B | 1.23B | 1.82B | 1.55B |
| EBITDA | 867.10M | 670.50M | 755.70M | 1.33B | 811.96M |
| Net Income | 265.60M | 175.10M | 309.70M | 876.10M | 414.40M |
Balance Sheet | |||||
| Total Assets | 8.02B | 8.26B | 7.74B | 5.07B | 3.95B |
| Cash, Cash Equivalents and Short-Term Investments | 426.10M | 688.80M | 126.10M | 133.00M | 237.35M |
| Total Debt | 2.75B | 2.87B | 3.68B | 1.14B | 625.52M |
| Total Liabilities | 3.89B | 4.23B | 5.07B | 2.55B | 2.22B |
| Stockholders Equity | 4.09B | 3.99B | 2.64B | 2.45B | 1.66B |
Cash Flow | |||||
| Free Cash Flow | 145.40M | 475.30M | 156.10M | 181.70M | 371.98M |
| Operating Cash Flow | 538.60M | 815.10M | 629.70M | 612.30M | 695.97M |
| Investing Cash Flow | -397.70M | -340.00M | -2.72B | -957.50M | -465.23M |
| Financing Cash Flow | -389.20M | 84.90M | 1.99B | 220.70M | -69.27M |
Sartorius Stedim Biotech Technical Analysis
Positive
180.80
Price Trends
172.00
Positive
188.88
Negative
187.29
Negative
Market Momentum
-0.53
Negative
54.43
Neutral
62.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Positive. The current price of 180.8 is above the 20-day moving average (MA) of 167.59, above the 50-day MA of 172.00, and below the 200-day MA of 187.29, indicating a neutral trend. The MACD of -0.53 indicates Negative momentum. The RSI at 54.43 is Neutral, neither overbought nor oversold. The STOCH value of 62.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:DIM.
Sartorius Stedim Biotech Peers Comparison
UnderperformOutperform
Sector (55)
FR:DIM
Sartorius Stedim Biotech
180.80
8.60
4.99%
FR:BIM
bioMerieux
91.75
-26.17
-22.19%
FR:ERF
Eurofins Scientific
68.48
18.33
36.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.